nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrimethamine—DHFR—Methotrexate—lymphatic system cancer	0.724	0.841	CbGbCtD
Pyrimethamine—CYP2C9—Teniposide—lymphatic system cancer	0.137	0.159	CbGbCtD
Pyrimethamine—Anaemia megaloblastic—Methotrexate—lymphatic system cancer	0.00745	0.0535	CcSEcCtD
Pyrimethamine—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.00545	0.0391	CcSEcCtD
Pyrimethamine—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00434	0.0312	CcSEcCtD
Pyrimethamine—Pancytopenia—Teniposide—lymphatic system cancer	0.00402	0.0288	CcSEcCtD
Pyrimethamine—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00387	0.0278	CcSEcCtD
Pyrimethamine—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00358	0.0257	CcSEcCtD
Pyrimethamine—Pancytopenia—Fludarabine—lymphatic system cancer	0.00353	0.0253	CcSEcCtD
Pyrimethamine—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00329	0.0236	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00326	0.0234	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00319	0.0229	CcSEcCtD
Pyrimethamine—Haematuria—Fludarabine—lymphatic system cancer	0.00316	0.0227	CcSEcCtD
Pyrimethamine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00311	0.0223	CcSEcCtD
Pyrimethamine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00284	0.0204	CcSEcCtD
Pyrimethamine—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00281	0.0202	CcSEcCtD
Pyrimethamine—Leukopenia—Teniposide—lymphatic system cancer	0.00264	0.0189	CcSEcCtD
Pyrimethamine—Pancytopenia—Bleomycin—lymphatic system cancer	0.00259	0.0186	CcSEcCtD
Pyrimethamine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0024	0.0173	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00235	0.0169	CcSEcCtD
Pyrimethamine—Leukopenia—Fludarabine—lymphatic system cancer	0.00232	0.0166	CcSEcCtD
Pyrimethamine—Haematuria—Bleomycin—lymphatic system cancer	0.00232	0.0166	CcSEcCtD
Pyrimethamine—Anorexia—Teniposide—lymphatic system cancer	0.00229	0.0165	CcSEcCtD
Pyrimethamine—Pancytopenia—Carmustine—lymphatic system cancer	0.00226	0.0162	CcSEcCtD
Pyrimethamine—Pancytopenia—Vincristine—lymphatic system cancer	0.00216	0.0155	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00211	0.0152	CcSEcCtD
Pyrimethamine—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.0021	0.0151	CcSEcCtD
Pyrimethamine—Decreased appetite—Teniposide—lymphatic system cancer	0.00209	0.015	CcSEcCtD
Pyrimethamine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00207	0.0149	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00207	0.0149	CcSEcCtD
Pyrimethamine—Anorexia—Fludarabine—lymphatic system cancer	0.00201	0.0145	CcSEcCtD
Pyrimethamine—Haematuria—Mitoxantrone—lymphatic system cancer	0.00188	0.0135	CcSEcCtD
Pyrimethamine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00184	0.0132	CcSEcCtD
Pyrimethamine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00177	0.0127	CcSEcCtD
Pyrimethamine—Leukopenia—Bleomycin—lymphatic system cancer	0.0017	0.0122	CcSEcCtD
Pyrimethamine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00156	0.0112	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00155	0.0111	CcSEcCtD
Pyrimethamine—Vomiting—Teniposide—lymphatic system cancer	0.00153	0.011	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00152	0.0109	CcSEcCtD
Pyrimethamine—Leukopenia—Carmustine—lymphatic system cancer	0.00148	0.0106	CcSEcCtD
Pyrimethamine—Anorexia—Bleomycin—lymphatic system cancer	0.00148	0.0106	CcSEcCtD
Pyrimethamine—Leukopenia—Vincristine—lymphatic system cancer	0.00142	0.0102	CcSEcCtD
Pyrimethamine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00138	0.0099	CcSEcCtD
Pyrimethamine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00135	0.00967	CcSEcCtD
Pyrimethamine—Vomiting—Fludarabine—lymphatic system cancer	0.00134	0.00965	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00132	0.00951	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00129	0.00927	CcSEcCtD
Pyrimethamine—Anorexia—Carmustine—lymphatic system cancer	0.00129	0.00926	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00126	0.00908	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00126	0.00903	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00123	0.00884	CcSEcCtD
Pyrimethamine—Anorexia—Vincristine—lymphatic system cancer	0.00123	0.00884	CcSEcCtD
Pyrimethamine—Anorexia—Mitoxantrone—lymphatic system cancer	0.0012	0.0086	CcSEcCtD
Pyrimethamine—Decreased appetite—Carmustine—lymphatic system cancer	0.00118	0.00844	CcSEcCtD
Pyrimethamine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00115	0.00824	CcSEcCtD
Pyrimethamine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00114	0.0082	CcSEcCtD
Pyrimethamine—Decreased appetite—Vincristine—lymphatic system cancer	0.00112	0.00806	CcSEcCtD
Pyrimethamine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00109	0.00785	CcSEcCtD
Pyrimethamine—Pancytopenia—Methotrexate—lymphatic system cancer	0.00105	0.00751	CcSEcCtD
Pyrimethamine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000997	0.00715	CcSEcCtD
Pyrimethamine—Vomiting—Bleomycin—lymphatic system cancer	0.000985	0.00707	CcSEcCtD
Pyrimethamine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000974	0.00699	CcSEcCtD
Pyrimethamine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000951	0.00683	CcSEcCtD
Pyrimethamine—Haematuria—Methotrexate—lymphatic system cancer	0.000937	0.00672	CcSEcCtD
Pyrimethamine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000926	0.00665	CcSEcCtD
Pyrimethamine—Vomiting—Carmustine—lymphatic system cancer	0.00086	0.00617	CcSEcCtD
Pyrimethamine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000834	0.00599	CcSEcCtD
Pyrimethamine—Vomiting—Vincristine—lymphatic system cancer	0.000821	0.00589	CcSEcCtD
Pyrimethamine—Vomiting—Mitoxantrone—lymphatic system cancer	0.0008	0.00574	CcSEcCtD
Pyrimethamine—Leukopenia—Methotrexate—lymphatic system cancer	0.000687	0.00493	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000627	0.0045	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000613	0.0044	CcSEcCtD
Pyrimethamine—Anorexia—Methotrexate—lymphatic system cancer	0.000597	0.00429	CcSEcCtD
Pyrimethamine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000545	0.00391	CcSEcCtD
Pyrimethamine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000462	0.00331	CcSEcCtD
Pyrimethamine—Vomiting—Methotrexate—lymphatic system cancer	0.000398	0.00286	CcSEcCtD
